We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Investigate Atezolizumab Subcutaneous in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03735121
Recruitment Status : Active, not recruiting
First Posted : November 8, 2018
Last Update Posted : September 7, 2022
Sponsor:
Information provided by (Responsible Party):
Hoffmann-La Roche

Brief Summary:
This study will evaluate the pharmacokinetics, safety, and efficacy of atezolizumab subcutaneous (SC) compared with atezolizumab IV in participants with locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) who have not been exposed to cancer immunotherapy (CIT) and for whom prior platinum-based therapy has failed. The study is comprised of two parts, as follows: A dose-finding part (Part 1, Phase Ib) will aim to identify the dose of atezolizumab SC to be tested in Part 2. A dose-confirmation part (Part 2, Phase III, randomized) will aim to confirm that the dose moved forward from Part 1 yields drug exposure that is comparable to that of atezolizumab IV.

Condition or disease Intervention/treatment Phase
Non-Small Cell Lung Cancer Drug: Atezolizumab Drug: rHuPH20 Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 438 participants
Allocation: Randomized
Intervention Model: Sequential Assignment
Intervention Model Description: Intervention study model can be sequential or in parallel.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized, Multicenter, Phase Ib/III Study to Investigate the Pharmacokinetics, Efficacy, and Safety of Atezolizumab Subcutaneous Compared With Atezolizumab Intravenous in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Actual Study Start Date : December 27, 2018
Actual Primary Completion Date : April 21, 2022
Estimated Study Completion Date : May 31, 2024

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lung Cancer

Arm Intervention/treatment
Experimental: Atezolizumab (Part 2)
Atezolizumab
Drug: Atezolizumab
Atezolizumab will be administered as per the schedule specified in arm or cohort.
Other Name: Tecentriq

Experimental: Cohort 1: Atezolizumab+rHuPH20 (Part 1)
Atezolizumab+rHuPH20, followed by Atezolizumab
Drug: Atezolizumab
Atezolizumab will be administered as per the schedule specified in arm or cohort.
Other Name: Tecentriq

Drug: rHuPH20
rHuPH20 will be administered as per the scheduled specified in the cohort for Part 1.
Other Name: ENHANZE

Experimental: Cohort 2: Atezolizumab+rHuPH20 (Part 1)
Atezolizumab+rHuPH20, followed by Atezolizumab
Drug: Atezolizumab
Atezolizumab will be administered as per the schedule specified in arm or cohort.
Other Name: Tecentriq

Drug: rHuPH20
rHuPH20 will be administered as per the scheduled specified in the cohort for Part 1.
Other Name: ENHANZE

Experimental: Cohort 3: Atezolizumab+rHuPH20(Part 1)
Atezolizumab+rHuPH20, followed by Atezolizumab
Drug: Atezolizumab
Atezolizumab will be administered as per the schedule specified in arm or cohort.
Other Name: Tecentriq

Drug: rHuPH20
rHuPH20 will be administered as per the scheduled specified in the cohort for Part 1.
Other Name: ENHANZE

Experimental: Atezolizumab + rHuPH20 (Part 2)
Atezolizumab + rHuPH20
Drug: Atezolizumab
Atezolizumab will be administered as per the schedule specified in arm or cohort.
Other Name: Tecentriq

Drug: rHuPH20
rHuPH20 will be administered as per the scheduled specified in the cohort for Part 1.
Other Name: ENHANZE




Primary Outcome Measures :
  1. Observed Concentration of Atezolizumab in Serum at Cycle 1 in Part 1 [ Time Frame: Predose of Cycle 2. Cycle length is 14 days or 21 days. ]
  2. Observed Concentration of Atezolizumab in Serum at Cycle 1 in Part 2 [ Time Frame: Predose of Cycle 2. Cycle length is 21 days. ]
  3. Area Under the Concentration-Time Curve from Time Zero to 21 Days (AUC₀-₂₁) of Atezolizumab in Part 2 [ Time Frame: At Cycle 1. Cycle length is 21 days. ]

Secondary Outcome Measures :
  1. Concentration at the End of a Dosing Interval (Ctrough) of Atezolizumab in Part 1 [ Time Frame: At pre-defined intervals from first administration of study drug up to treatment discontinuation visit (up to approximately 5.3 years). ]
  2. Maximum Observed Serum Concentration (Cmax) of Atezolizumab in Part 1 [ Time Frame: At pre-defined intervals from first administration of study drug up to treatment discontinuation visit (up to approximately 5.3 years). ]
  3. Time to Maximum Plasma Concentration (Tmax) of Atezolizumab in Part 1 [ Time Frame: At pre-defined intervals from first administration of study drug up to treatment discontinuation visit (up to approximately 5.3 years). ]
  4. Serum Atezolizumab Concentration During SC Administration in Part 1 [ Time Frame: At pre-defined intervals from first administration of study drug up to treatment discontinuation visit (up to approximately 5.3 years). ]
  5. Percentage of Participants with Adverse Events in Part 1 and Part 2 [ Time Frame: Up to end of the study (approximately 5.3 years) ]
  6. Model-Predicted Ctrough at Cycle 1 (Ctrough Cycle 1) of Atezolizumab in Part 2 [ Time Frame: Predose of Cycle 2. Cycle length is 21 days. ]
  7. Model-Predicted Ctrough at Steady Stage (Ctrough,ss) of Atezolizumab in Part 2 [ Time Frame: At pre-defined intervals from first administration of study drug up to treatment discontinuation visit (up to approximately 5.3 years). ]
  8. Model-Predicted AUC at Steady Stage (AUCss) of Atezolizumab in Part 2 [ Time Frame: At pre-defined intervals from first administration of study drug up to treatment discontinuation visit (approximately 5.3 years). ]
  9. Overall Patient-Reported Adverse Event Burden Over Time in Part 2 [ Time Frame: Up to treatment discontinuation visit (up to approximately 5.3 years) ]
  10. Objective Response Rate (ORR) in Part 2 [ Time Frame: Up to treatment discontinuation visit (up to approximately 5.3 years) ]
    ORR is defined as the proportion of patients with a partial response (PR) or complete response (CR) as determined by the investigator according to RECIST v1.1.

  11. Progression-Free Survival (PFS) in Part 2 [ Time Frame: Up to treatment discontinuation visit (up to approximately 5.3 years) ]
    PFS is defined as the time from the date of study entry to the date of documented disease progression, as determined by the investigator according to RECIST v1.1, or death from any cause, whichever is earlier.

  12. Overall Survival (OS) in Part 2 [ Time Frame: Up to 5.3 years ]
  13. Duration of Response (DOR) in Part 2 [ Time Frame: Up to treatment discontinuation visit (up to approximately 5.3 years) ]
    Duration of response (DOR), defined as the time from first occurrence of a documented objective response to disease progression or death from any cause (whichever occurs first), as determined by the investigator according to RECIST v1.1.

  14. Functioning and Global Health Status Over Time in Part 2 [ Time Frame: Up to treatment discontinuation visit (up to approximately 5.3 years) ]
  15. Overall Satisfaction With Treatment in Part 2 [ Time Frame: Up to treatment discontinuation visit (up to approximately 5.3 years) ]
    Overall satisfaction with treatment, as assessed by the modified satisfaction with therapy (SWT) scale of the Cancer Therapy Satisfaction Questionnaire (CTSQ).

  16. Percentage of Participants With ADAs to Atezolizumab in Part 2 [ Time Frame: Baseline to pre-defined intervals up treatment discontinuation (approximately 5.3 years) ]
    Percentage of participants with ADAs to atezolizumab after SC administration or IV administration relative to the prevalence of ADAs at baseline.

  17. Percentage of Participants Wtih ADAs to rHuPH20 in Part 2 [ Time Frame: Baseline to pre-defined intervals up to treatment discontinuation (approximately 5.3 years) ]
    Percentage of participants with ADAs to rHuPH20 after SC administration relative to the prevalence of ADAs at baseline.

  18. Convenience, Potential Time Savings, and Overall Satisfaction With Atezolizumab SC Compared With Atezolizumab IV in Part 2 [ Time Frame: Up to 5.3 years ]
    Convenience, potential time savings, and overall satisfaction with atezolizumab SC compared with atezolizumab IV, as assessed by the HCP SC versus IV Perspective Questionnaire.

  19. Convenience, Ease of Administration, and Overall Satisfaction With Atezolizumab SC in Part 2 [ Time Frame: Up to 5.3 years ]
    Convenience, ease of administration, and overall satisfaction with atezolizumab SC, as assessed by the HCP Subcutaneous Perspective Questionnaire.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically or cytologically documented locally advanced or metastatic NSCLC
  • Prior platinum-containing regimen or disease recurrence ≤ 6 months since prior platinum-based adjuvant/neoadjuvant regimen.
  • Measurable disease as defined by RECIST v1.1
  • ECOG Performance Status of 0 or 1
  • Life expectancy ≥12 weeks
  • Adequate hematologic and end-organ function

Additional Inclusion Criteria (Part 2 Only) • Availability of tissue and known EGFR status

Exclusion Criteria:

  • Symptomatic, untreated, or actively progressing CNS metastases
  • Uncontrolled or symptomatic hypercalcemia
  • Pregnancy or breastfeeding
  • Active or history of autoimmune disease or immune deficiency
  • History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis
  • Severe infection ≤ 4 weeks
  • Treatment with therapeutic oral or IV antibiotics ≤ 2 weeks prior to study treatment
  • Significant cardiovascular disease
  • Prior allogeneic stem cell or solid organ transplantation
  • Treatment with a live, attenuated vaccine ≤ 4 weeks
  • Treatment with systemic immunostimulatory agents ≤ 4 weeks or 5 half-lives of the drug
  • Treatment with systemic immunosuppressive medication ≤ 2 weeks

Additional Exclusion Criteria (Part 2 Only)

• Tested tumor PD-L1 expression status with an intention to treat the patient if positive


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03735121


Locations
Show Show 94 study locations
Sponsors and Collaborators
Hoffmann-La Roche
Investigators
Layout table for investigator information
Study Director: Clinical Trials Hoffmann-La Roche
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Hoffmann-La Roche
ClinicalTrials.gov Identifier: NCT03735121    
Other Study ID Numbers: BP40657
First Posted: November 8, 2018    Key Record Dates
Last Update Posted: September 7, 2022
Last Verified: September 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Atezolizumab
Antineoplastic Agents